Afleveringen
-
In this episode, host Shikha Jain, MD, speaks with Sean Bohen, MD, about how cancer therapies are changing how oncology can be discussed, shifting from clinical to industry work and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Bohen 1:04
• The interview 1:30
• Tell us about your journey. How did you become an oncologist, and how did you make the transition into working in the pharmaceutical industry? 1:51
• How did you end up at Olema Oncology after working with other pharmaceutical companies? What was your decision-making process to focus on the industry part of your career? 3:44
• Tell us more about what Olema Oncology does and what your role is there. 6:30
• What do you see coming down the pipeline for breast cancer research and innovation? … What do you think Olema will contribute to that space? 8:58
• Bohen and Jain on the ways in which new treatments have resulted in shifting conversations around cancer care and patient quality of life. 12:45
• If someone in fellowship is interested in working in industry, pharmaceuticals or scientific development, what are the most effective ways to get into this space? 18:21
• Jain and Bohen on changing the mindset and misconceptions around moving between clinical, academic and industry work within the field and after fellowship. 20:52
• What do you see happening in the oncology landscape twenty years from now? 25:46
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 29:19
• How to contact Bohen 30:54
• Thanks for listening 31:52
Sean Bohen, MD, is the President and CEO of Olema Oncology.We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Bohen can be reached at olema.com.
Disclosures: Jain and Bohen report no relevant financial disclosures. -
In this episode, host Shikha Jain, MD, speaks with Jonathan D. Licht, MD, about becoming and training qualified leaders in the field, challenges facing health care leaders and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Licht 1:16
• The interview 3:17
• Can you tell us about your journey into hematology-oncology and how you ended up where you are today? 3:58
• How have you found the time and ability to balance and succeed in the research, clinical, translational and leadership parts of your work? 9:05
• What do you suggest to people who are currently trying to get into leadership positions in their early-to-mid career? 12:52
• Do you agree with the sentiment that there are some leaders in the field who are put into positions prematurely or are ineffective? As a leader, how do you address the need for further training of future leaders? 18:39
• What are some of the leadership challenges you have seen in the last several years, and how have you managed to navigate them? 23:20
• How did you use your leadership skills to navigate the first few years of the pandemic, and how are you continuing to navigate delivery of care post-pandemic? 29:23
• Tell me about the process of achieving NCI designation and what it means for your institution. 36:25
• How have you had to navigate state health care legislation and policies challenging reproductive health care? 42:16
• If someone could only listen to the last minute of this episode, what would you want them to take away? 46:13
• How to contact Licht 46:56
• Thanks for listening 48:16
Jonathan D. Licht, MD, is the director of the University of Florida Health Cancer Center.We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Licht can be reached on X, formerly known as Twitter, @jdlicht or via email [email protected].
Disclosures: Jain reports no relevant financial disclosures. Licht reports consultancy for AstraZeneca and research funding for Epizyme. -
Zijn er afleveringen die ontbreken?
-
In this episode, host Shikha Jain, MD, speaks with Aparna Parikh, MD, about cancer and GI malignancies in the global health space, circulating tumor DNA in the field of oncology and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Parikh 1:07
• The interview 2:08
• What was your path into medicine, cancer care and GI oncology? 2:35
• Tell us about what you do in the global health space and what your thoughts are on colon cancer and GI malignancies in the global health space. 8:07
• Why are we seeing so many more young people being diagnosed with colon cancer in the US and internationally? 12:24
• Do you think US lifestyle and Western diets compared to the rest of the world have contributed to the rise of early colon cancer diagnoses? 15:04
• How can physicians talk about lifestyle, diet and environmental/social determinants of health that impact a cancer diagnosis? 17:52
• Can you provide a brief overview of what is circulating tumor DNA (ctDNA) and liquid biopsy, and how are we using it in this space? 19:44
• Jain and Parikh on ctDNA as an innovation can be transformative in the field of GI oncology. 24:06
• What are your predictions for GI oncology in the next ten to twenty years? 26:06
• If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:44
• How to contact Parikh 30:57
• Thanks for listening 31:57
Aparna Parikh, MD, is a GI oncologist at the MGH Cancer Center where she directs the colorectal research program and young adults CRC program. She is an associate professor at Harvard Medical School and an international expert in CRC and liquid biopsies.We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Parikh can be reached via email [email protected].
Disclosures: Jain reports no relevant financial disclosures. Parikh reports equity in C2i Genomics XGenomes Cadex and Parithera. Advisor/consultant for Abbvie, AZ, Bayer, Biofidelity, Checkmate Pharmaceuticals, CVS, Delcath, Eli Lilly, FMI, Guardant, Hookipa, Illumina, Inivata, Mirati, Pfizer, Saga, Seagen, Taiho, Scare Inc, Science For America, and Value Analytics Lab. She receives fees from Up to Date. She has received travel fees from Karkinos Healthcare. She has been on the DSMC for a Roche study and on Steering Committee for Exilixis. She has received research funding to the Institution from BMS, Daiichi Sankyo, Erasca, Genentech, Mirati, Novartis, PMV Pharmaceuticals, Plexxicon, PureTech, Takeda and Syndax. -
In this episode, host Shikha Jain, MD, speaks with Barnaby Balmforth, PhD, about the evolution of genomics in cancer care, the impact of personalized care tools and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Balmforth 1:12
• The interview 3:01
• How did you get to where you are today? What drove you to become a leader in this space? 3:45
• What is genomics, and why is genomic analysis important in cancer care? 7:18
• Jain and Balmforth on the evolution of technology and challenges facing genomics and diagnostic testing to achieve personalized care for individual patients. 11:59
• In addition to time, can you speak on the challenge of access for this type of technology? 13:20
• How have you been able to implement “next day” test results and reports of your technology? 17:50
• Jain and Balmforth on how Biofidelity’s technology can transform the delivery of care, as well as its psychological and mental impact. 19:06
• What’s coming down the line for you and Biofidelity? 20:56
• What are your thoughts for when you expand beyond thoracic oncology? What are your long-term visions for other disease sites? 24:19
• Do you have any thoughts on AI and how it may influence genomics in cancer care? 25:51
• If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:37
• How to contact Balmforth 30:37
• Thanks for listening 31:10
Barnaby Balmforth, PhD, is co-founder and CEO of Biofidelity. Barnaby has more than 15 years’ experience in the leadership of multidisciplinary technology development.We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Balmforth can be reached via the Biofidelity website.
Disclosures: Jain reports no relevant financial disclosures. Balmforth reports he is an employee of Biofidelity and owns shares in the company. -
In this episode, host Shikha Jain, MD, speaks with Christina Gomez, MD, about the power of patients’ voices, finding joy in physicians work-life balance and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Gomez 1:09
• The interview 1:45
• How did you get to where you are today as a GI oncologist? 2:02
• Have you seen an increase in young people with GI malignancies, and do you have any thoughts as to why we are seeing this change? 5:23
• Where did the inspiration for your book, Stopped in My Tracks: A Physician's Collection of Cancer Patients' Quotes, come from? 9:08
• Jain and Gomez on the power of patient voices. 12:41
• Thoughts on creating another book? 15:30
• Where do you see the landscape of oncology going in the age of machine-learning and new technologies? 17:05
• Jain and Gomez on the different ways physicians can demonstrate personalized care for patients. 21:00
• What should we do as oncologists and as a society to prevent burnout in health care professionals? 24:00
• Jain and Gomez on the mindset shift on work-life-balance for physicians. 27:33
• Jain and Gomez on motherhood and how it can define patient interactions and delivery of care. 29:51
• If someone could only listen to the last few minutes of this episode, what would you want them to take away? 34:41
• How to contact Gomez 36:07
• Thanks for listening 37:31
Christina Gomez, MD, is a gastrointestinal medical oncologist at Banner MD Anderson Cancer Center.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Gomez can be reached at christinagomezmd.com, via Facebook or on Instagram @christygomezmd.
Disclosures: Jain and Gomez report no relevant financial disclosures. -
In this episode, host Shikha Jain, MD, speaks with Ashley Sumrall, MD, about advocacy outside of their oncology practices and organizations, what lies ahead for the field of neuro-oncology and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Sumrall 1:16
• The interview 2:54
• How did you end up in the neuro-oncology space? 3:21
• As a neuro-oncologist, how do you stay up-to-date with neurology, oncology and medicine? 7:28
• Is there a difference in the way you interact with a neuro-oncologist versus a medical oncologist? 8:58
• What drove you to get into the advocacy space? 10:09
• Do you predominantly do advocacy work through ASCO, or do you do it through other avenues as well? 12:20
• If someone is interested in getting involved in becoming an advocate with ASCO, on the local level or on the national level, what is the best way for them to start that process? 15:24
• How do you talk to people in and outside of organizations about current situations facing health care? 19:40
• If people are interested in learning more about the AMA or getting involved with an organization like the AMA, how can they do so? 22:31
• What do you see coming down the pipeline that you think is going to transform the neuro-oncology space? 27:16
• If someone could only listen to the last minute of this episode, what would you want them to take away? 30:04
• How to contact Sumrall 32:13
• Thanks for listening 32:56
Ashley L. Sumrall, MD, is a neuro-oncologist practicing at Levine Cancer Institute in Charlotte, NC.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sumrall can be reached on X, formerly known as Twitter: @AshleySumrallMD.
Disclosures: Jain reports no relevant financial disclosures. Sumrall reports receiving funding from Bristol-Myers Squibb, Exelixis, Kura Oncology, Novocure and Oncoceutics, and being a consultant for Abbvie, Athenex, Bayer, Exelixis and Novocure. -
In this episode, host Shikha Jain, MD, speaks with George Sledge, MD, about patient feedback benefiting leadership decision-making, the future of precision medicine in oncology and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Sledge 1:03
• The interview 2:59
• How did you become an oncologist? 3:24
• Tell us about your journey into leadership in oncology. 5:27
• Did you continue to see patients while leading organizations? 7:48
• Jain and Sledge on learning from conversations and experiences with patients. 10:57
• How did you end up in your previous position as ASCO president? 12:29
• Do you feel that ASCO is an organization that is adept at adapting to change? 14:37
• Tell us about Caris Life Sciences and how you pivoted to your role as executive vice president and CMO there. 18:44
• Where do you see the future of oncology going? 23:00
• Jain and Sledge on the concerns surrounding artificial intelligence and technology in cancer care and the doctor patient relationship. 26:31
• What is something aspirational that you think could change the way we deliver cancer care years from now? 31:11
• If someone could only listen to the last minute of this episode, what would you want them to take away? 35:21
• How to contact Sledge 36:37
• Thanks for listening 37:10
George Sledge, MD, serves as executive vice president and chief medical officer at Caris Life Sciences.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sledge can be reached via email [email protected].
Disclosures: Jain reports no relevant financial disclosures. Sledge reports that he has stock options with Syndax. -
In this episode, host Shikha Jain, MD, speaks with Jan Kitajewski, PhD, about blending community need with scientific advancement, his role as the director of a cancer care center and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Kitajewski 1:08
• The interview 2:59
• Tell me about how you started and your pathway to this position. 3:26
• You have a very diverse background in various fields of medicine. Was there something that drew you to lead a cancer center? 6:15
• What are your thoughts on how institutions can shift their mindsets toward setting up research that is more inclusive of patient diversity in clinical trials? 9:44
• Jain and Kitajewski on The Immortal Life of Henrietta Lacks, mistrust in the health care system, and how institutions can empower their communities. 14:00
• What does a cancer center director do, and what are some things that people may be surprised to know about your position? 16:30
• Jain and Kitajewski on the University of Illinois Cancer Center applying for NCI designation, and what the process entails. 22:05
• Jain and Kitajewski on the challenges and successes that come with physician leadership when making changes at an institution. 29:28
• What is your vision for the future of the University of Illinois Cancer Center? 34:16
• If someone could only listen to the last minute of this episode, what would you want them to take away? 40:13
• How to contact Kitajewski 40:55
• Thanks for listening 41:35
Jan Kitajewski, PhD, is director of the University of Illinois Cancer Center and a professor and head of the department of physiology and biophysics.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Kitajewski can be reached via email [email protected].
Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Kitajewski at the time of posting. -
In this episode, host Shikha Jain, MD, speaks with Avital O’Glasser, MD, about the challenges facing non-traditional scholarship, amplifying diverse voices in medicine and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About O’Glasser 1:15
• The interview 2:36
• Jain and O’Glasser on their friendship and how they met. 2:52
• What is non-traditional scholarship, and why is it so difficult for academics to adopt to these practices? 5:16
• Jain and O’Glasser on the added value of non-traditional scholarship in academia and engagement. 11:25
• How can engaging in non-traditional scholarship be leveraged and disseminated along with more “traditionally” recognized ways of CME? 13:33
• O’Glasser on Daniel Cabrera’s More Than Likes and Tweets: Creating Social Media Portfolios for Academic Promotion and Tenure and Ernest Boyer’s The Scholarship of Engagement. 17:19
• Jain and O’Glasser on utilizing digital abstracts in presenting data and pushing back on non-promotable work. 18:30
• How can physicians make sure that information reaches its desired audience through non-traditional scholarship, or provide more educational opportunities about this work? 22:29
• About An Evolution of Empowerment: Voices of Women in Medicine and Their Allies, co-edited by Jain and O’Glasser, and their process in creating this publication. 24:28
• Do you think we’ll collaborate on another book? 32:22
• If someone could only listen to the last few minutes of this episode, what would you want them to take away? 35:47
• How to contact O’Glasser 36:45
• Thanks for listening 38:08
Avital O’Glasser, MD, FACP, FHM, is a hospitalist and associate professor of medicine at Oregon Health & Science University. Her clinical practice focus is perioperative medicine, and she is also the assistant program director for social media and scholarship for OHSU’s Internal Medicine Residency Program.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. O’Glasser can be reached on the Women In Medicine blog.
Disclosures: Jain and O’Glasser report no relevant financial disclosures. -
In this episode, host Shikha Jain, MD, speaks with St. Jude’s Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Gottschalk 1:12
• About Velasquez 1:57
• The interview 2:23
• About Gottschalk’s journey and how he ended up in this space. 2:56
• About Velasquez’s journey and how she ended up in this space. 4:16
• Gottschalk on the history of severe combined immune deficiency (SCID), or “bubble boy disease” and his work on developing the cure. 5:04
• When you think about what we have learned about immunotherapy, immune systems and cancer treatment over the last fifty years, did you think we would be where we are today in cancer care? 7:27
• How have CAR T-cells transformed health care so far, and what will they do for the future? 8:53
• What are you currently working on, and what excites you most about that work? 9:57
• Do you think that we can expect a transformation in CAR T-cells being used in solid tumors in the future? 12:34
• How do we prioritize enhanced CAR T-cells in clinical studies? 13:38
• How can we address the challenges facing the delivery of CAR T-cell therapy and make it more accessible to patients? 17:04
• Where do you see CAR T-cell therapy going in cancer care and in immunodeficiencies? 21:03
• If you were interviewed again in five years, what do you think you will be doing then, and what do you think we will be talking about? 25:42
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 30:31
• How to contact Gottschalk and Velasquez 31:22
• Thanks for listening 31:51Stephen Gottschalk, MD, St. Jude Department of bone marrow transplantation and cellular therapy chair, focuses his research on cancer immunotherapy, cell therapy and stem cell transplantation. The Gottschalk laboratory focuses on Epstein-Barr virus-specific T cells for treating EBV-associated cancers and using genetically modified T cells for cancer immunotherapy.
Paulina Velasquez, MD, St. Jude Department of bone marrow transplantation and cellular therapy, has made significant contributions to the field of immunotherapy, developing novel T-cell therapy platforms for pediatric hematological malignancies. Her team is pursuing projects that address antigen discovery, tumor immune evasion, persistence and efficacy of CAR T cells and cell-cell interaction within the tumor microenvironment.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Gottschalk can be reached via email [email protected]. Velasquez can be reached via email [email protected].
Disclosures: Jain reports no relevant financial disclosures. Gottschalk reports he is co-inventor on patents and patent applications in the fields of cell or gene therapy for cancer, a member of the scientific advisory board of Be Biopharma and CARGO, and the data and safety monitoring board (DSMB) of Immatics and has received honoraria from TESSA Therapeutics. Velasquez reports patent applications in the field of T-cell immunotherapy.
-
In this episode, host Shikha Jain, MD, speaks with Erica Barnell, MD, PhD, about Geneoscopy’s non-invasive screening and early detection technology, helping improve patient compliance for gastrointestinal health and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Barnell 1:07
• The interview 2:05
• Tell me about how you got into this space and co-founded your unique company. 2:30
• How did you find the time to co-find a company on top of completing your PhD program? 4:24
• Barnell on starting Geneoscopy with her brother and working with family. 5:06
• What were the steps you took to make the idea of Geneoscopy happen? 6:08
• Describe the process and technology Geneoscopy is using for early colorectal cancer screening. 7:33
• What makes your non-invasive screening tests different from others? 9:29
• Do you have any advice on how to execute a timeline for physicians and scientists who may have ideas like yours? 11:08
• Jain and Barnell on the advantages of partnering with your network and connections to navigate the challenges of standing up entrepreneurial ventures. 13:36
• How can physicians find resources outside of their network to help them successfully build a company and execute their ideas? 15:20
• Tell me more about what Geneoscopy is looking at outside of cancer. 17:40
• Is this technology something that patients can order directly, and are you thinking of expanding this globally in the future? 19:25
• What do you envision for Geneoscopy ten years down the line? 20:37
• Have you received feedback from other physicians? 21:39
• Jain and Barnell on the positive results of patient compliance with non-invasive screening tests. 23:09
• What’s next for you? Along with growing Geneoscopy, is there anything else that you are working on and passionate about? 24:54
• Can you talk about how Geneoscopy has focused on equitable access in this space? 27:15
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 29:45
• How to contact Barnell 30:20
• Thanks for listening 31:02Erica Barnell, MD, PhD, is the chief science officer and co-founder of Geneoscopy, a life sciences company focused on transforming gastrointestinal health by empowering patients and providers with innovative tests that help detect, prevent and monitor disease, including colorectal cancer.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Barnell can be reached on X, formerly known as Twitter, @EricaBarnell, or via Geneoscopy’s LinkedIn and Facebook and website, geneoscopy.com.
Disclosures: Jain reports no relevant financial disclosures. Barnell is the CSO and cofounder of Geneoscopy. -
In this episode, host Shikha Jain, MD, speaks with Laura Petrillo, MD, about navigating patients through changes and goals in palliative care, understanding patients living with and surviving advanced cancer and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Petrillo 1:03
• The interview 1:40
• How did you find yourself in medicine, specifically in palliative care and geriatrics? 2:04
• How has the evolution of cancer care and technology impacted the way you engage and deliver palliative care? 6:46
• Jain and Petrillo on the effect changes in palliative care can have on patients. 12:47
• How do you communicate the distinctions between palliative care and hospice care to patients and physicians? 17:19
• Do you think that there are ways for people outside of palliative care can incorporate intentional communication with patients in their care? … When should you refer someone to palliative care? 23:45
• Petrillo and Jain on advanced cancer survivorship and living with advanced cancer. 30:54
• Jain and Reynolds on the progress made in this space and the road ahead. 29:43
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 36:41
• How to contact Petrillo 38:30
• Thanks for listening 38:58Laura Petrillo, MD, is a palliative care physician-investigator in the Division of Palliative Care and Geriatrics at MGH and an assistant professor of medicine at Harvard Medical School.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Petrillo can be reached on X, formerly known as Twitter, @lpetrillz.
Disclosures: Jain and Petrillo report no relevant financial disclosures. -
In this episode, host Shikha Jain, MD, speaks with Kerry Reynolds, MD, about immunotherapy-related adverse events, creating educational resources on immunotherapy management and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Reynolds 1:06
• The interview 2:45
• Tell me about how your journey led you to this field of immunotherapy-related adverse events? 3:12
• Jain and Reynolds on how immunotherapy has changed how we talk about cancer care. 5:41
• How did you start the Severe Immunotherapy Complications Service? 6:16
• When you envision this program, what do you feel are the short-term and long-term goals? 10:47
• Can you tell me more about how you care for and manage in-patients through your program? 14:34
• As we learn more, do you think there will ever be a day where all immunotherapy side effects will be able to be managed in the outpatient setting? 16:34
• How do people get into this clinic, and what types of patients are admitted? 18:35
• Tell me about your book, Facing Immunotherapy: A Guide for Patients and Their Families. Who is the best audience for this book? 21:35
• Along with this book, are there other educational resources or initiatives that raise awareness for management of severe immunotherapy complications? 24:56
• Have you encountered any challenges or obstacles while creating and maintaining educational resources and research initiatives? 27:11
• Jain and Reynolds on the progress made in this space and the road ahead. 29:43
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 31:10
• How to contact Reynolds 32:40
• Thanks for listening 33:27Kerry Reynolds, MD, is an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Reynolds can be reached at MGH SIC, or via email [email protected].
Disclosures: Jain reports no relevant financial disclosures. Reynolds reports BMS Institutional research support and is on the advisory board for SAGA Diagnostics. -
In this episode, host Shikha Jain, MD, speaks with Amy Comander, MD, about incorporating lifestyle changes for cancer patients, developing lifestyle pathways for survivors and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Comander 1:14
• The interview 3:40
• How do you manage to incorporate running on such a high level into your day-to-day life? 4:04
• Tell us about what lifestyle medicine is and why it is so important to include in patient care? 6:43
• How do you suggest oncologists who are interested in integrating lifestyle medicine into their treatment plans communicate these changes to their patients? 10:06
• Jain and Comander on the importance of physical activity in cancer care. 12:09
• Do you have standard recommendations you give to patients to begin incorporating physical activity and exercise to their treatment plan? 13:34
• About Comander’s patient, and her Walk with Me movement. 16:13
• How do you incorporate lifestyle health into survivorship discussions after treatment? 17:12
• Jain and Comander on the evolution of medicine allowing there to be more metrics for holistic care and empowerment for patients. 19:02
• What types of clinical trials are there for lifestyle medicine? 21:19
• Comander on The Diet, Exercise, Lifestyles, and Cancer Prognosis Study (DELCaP). 21:45
• How do you talk to people who may not understand lifestyle medicine or its impact? 23:33
• Can you talk about the PAVING the Path to Wellness program? 24:54
• What is the training process for physicians looking to become a lifestyle medicine specialist? 28:40
• Is there an optimal way to incorporate these specialists in patients’ day-to-day without it being a burden for them? 31:11
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 33:13
• How to contact Comander 34:26
• Thanks for listening 35:37Amy Comander, MD, is a breast oncologist at the Massachusetts General Hospital Cancer Center.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Comander can be reached on via the MGH Cancer Center website, on Instagram and Threads @dramycomander or on X, formerly known as Twitter @DrAmyComander.
Disclosures: Jain and Comander report no relevant financial disclosures.
-
In this episode, host Shikha Jain, MD, speaks with Pia Chowdry, MD, about access to care in rural communities, how physicians can present information to patients and their caregivers and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Chowdry 1:04
• The interview 1:54
• What was your journey into oncology and how did you end up practicing in Louisiana? 2:07
• Can you talk about your work in racial and ethnic disparities, variables in cancer care, and prevention? 4:18
• Do you feel like being exposed to rural health care settings and challenges has changed the way you practice and talk about care to people outside the area? 6:19
• How do you navigate enrolling patients in rural areas into clinical trials? 10:35
• Jain and Chowdry on misconceptions surrounding clinical trial enrollment in rural areas. 12:42
• What excites you about your job and motivates you to avoid burnout? 13:48
• Has your experience as a caregiver for patients with cancer affected the ways in which you navigate patients and caregivers through treatment and care? 16:25
• Jain and Chowdry on the importance of how physicians present themselves to patients and caregivers. 19:39
• Chowdry and Jain on obstacles facing cancer care in rural areas, as well as benefits. 24:25
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 30:41
• How to contact Chowdry 31:54
• Thanks for listening 32:28Pia Chowdry, MD, is a medical oncologist with LSU Health in New Orleans, LA specializing in genitourinary malignancies.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Chowdry can be reached on X, formerly known as Twitter @Pia_Chowdry, or via email [email protected].
Disclosures: Jain and Chowdry report no relevant financial disclosures. -
In this episode, host Shikha Jain, MD, speaks with Douglas Micalizzi, MD, and Lecia Sequist, MD, about adopting novel technologies for early detection, public perception of prevention screening and more.
• Welcome to another exciting episode of Oncology Overdrive :58
• About Micalizzi 1:12
• About Sequist 2:26
• The interview 4:06
• Sequist’s background and how she got into the screening and prevention area of oncology 4:21
• Micalizzi on his chemistry background and how he got into this space 8:03
• About the evolution of early detection and MGH’s Cancer Early Detection and Diagnostics Clinic 11:47
• Who is involved in this clinic and how do you handle a patient’s panic over seeing cancer specialists? 14:30
• Discussion on the New York Times article Not Everything We Call Cancer Should Be Called Cancer and nomenclatures surrounding the various cancer stages and types 19:29
• Public perception of screening and the “push” from people outside of medicine 28:49
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 36:31
• How to contact Micalizzi and Sequist 37:51
• Thanks for listening 39:14Douglas Micalizzi, MD, is a medical oncologist at Massachusetts General Hospital specializing in breast cancer, early cancer detection and hereditary cancer risk.
Lecia V. Sequist, MD, MPH, is currently the Landry Family Professor of Medicine at Harvard Medical School, the Program Director for Cancer Early Detection and Diagnostics at MGH and the leader of the Cancer Risk, Prevention and Early Detection Program at the joint Dana-Farber/Harvard Cancer Center.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Micalizzi and Sequist can be reached through the Massachusetts General Hospital Cancer Early Detection and Diagnostics Clinic webpage. Sequist can also be reached on X, formerly known as Twitter @LeciaSequist.
Disclosures: Jain and Micalizzi report no relevant financial disclosures. Sequist reports her institution has received funds related to clinical trials from AstraZeneca, Delfi Diagnostics and Novartis. -
In this episode, host Shikha Jain, MD, speaks with Mettle Health’s Claritza Rios, MD, and Bridget Sumser, SW, about misconceptions surrounding palliative care, communication training as self-care for physicians and more.
• Welcome to another exciting episode of Oncology Overdrive :50
• About Sumser 1:07
• About Rios 1:52
• The interview 2:18
• About Rios and how she got into palliative care 2:47
• About Sumser’s journey and how she ended up in the palliative care space 4:15
• How do we approach the stigma of palliative care? How do we handle the misconception of palliative care and how can we change the narrative? 6:47
• Palliative care and hospice care 15:26
• Patient hope 24:21
• Communication training as a form of self-care 28:52
• Can you tell us about Mettle Health and how people can find you? 31:28
• Holistic care for patients 33:27
• Authenticity and being present for patients 36:58
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 43:26
• How to contact Rios and Sumser 45:52
• Thanks for listening 47:05Claritza Rios, MD, is a dedicated physician educator with extensive experience in emergency and internal medicine.
Bridget Sumser, SW, became a social worker to help people living with serious illness. Over the course of the last 10 years, she has worked across settings, providing support and companionship to patients, families, community members, and providers.We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sumser can be reached via email [email protected]. Rios can be reached on Instagram @claritzariosmd. Learn more about Mettle Health by visiting mettlehealth.com.
Disclosures: Jain reports no relevant financial disclosures. Rios is an MD in Internal Medicine; Emergency Medicine; Hospice and Palliative Medicine. Sumser is a Licensed Clinical Social Worker. -
In this episode, host Shikha Jain, MD, speaks with Cardinal Health’s Parisa Asgarisabet, PhD and Scott Swain, PhD, MPH about benefits and uses of real-world evidence, the issue of diversity in clinical trials and more.
• Welcome to another exciting episode of Oncology Overdrive 1:11
• About Swain 1:26
• About Asgarisabet 2:45
• The interview 3:30
• About Swain and how you ended up at Cardinal Health 3:50
• About Asgarisabet’s journey and how she ended up at Cardinal Health 5:09
• What is Cardinal Health and why should people know about the work they are doing? 6:37
• How is the work Cardinal Health is doing directly applicable to practicing oncologists? 7:30
• Jain, Asgarisabet, and Swain on Representation of age, race and ethnicity in real-world evidence (RWE), randomized clinical trial (RCT), and Surveillance, Epidemiology, and End Results (SEER) cancer patient registry data in advanced renal cell carcinoma (aRCC). 10:32
• How can we scale real world data in a bigger way and make this the standard as opposed to the exception? 14:02
• Jain and Swain on diversity, equity, and inclusion in the clinical trials design space 17:57
• Asgarisabet and Swain on the economic implications of a lack of diversity in clinical trials 19:53
• Swain and Jain on the importance of community engagement and outreach in achieving diversity of backgrounds in clinical trials 24:42
• What do you think are the next steps to implement real world data in order to make a larger impact? 27:38
• Should real world data be used in concert with randomized controlled trials or should this data be used independently? 29:02
• When we talk about these types of transformation in how we look at diseases and deciding the best plan of action, do you anticipate there being a challenge with insurance companies approving treatments using real world data? 30:27
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 35:18
• How to contact Swain and Asgarisabet 37:57
• Thanks for listening 39:13Scott Swain, PhD, MPH is a Director of Regulatory Science and Real-world Evidence with Cardinal Health.
Parisa Asgarisabet, PhD is a Lead statistician in the Real-World Evidence & Insights team at Cardinal Health.We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Asgarisabet can be reached via LinkedIn or via email [email protected]. Swain can be reached via LinkedIn or via email [email protected].
Disclosures: Jain reports no relevant financial disclosures. Asgarisabet and Swain are employees and shareholders of Cardinal Health. -
In this episode, hosts Shikha Jain, MD, Douglas H. Jones, MD, Amy Comander, MD, Dagny Zhu, MD, Don Dizon, MD, and Mark A. Lewis, MD, discuss the new social media platform, Threads and how physicians can use it for their practice.
• Welcome to another exciting episode of Oncology Overdrive :57
• The topic 1:10
• How many have created a profile on Threads? Why or why not? 2:59
• Dr. Jain has a Thread profile but is unsure how to get more engagement 3:20
• Dr. Lewis has convinced coworkers to use social media but has not used Threads yet 4:54
• Dr. Dizon has a Thread profile but notes that leaving other platforms is leaving those communities and starting all over on a new platform 6:25
• Giving Threads more time to pick up followers and engagement 11:18
• Dr. Zhu has a Thread profile and found it easy to create but engagement is not the same as other platforms 12:17
• Tips and tricks to sharing content on socials, especially Threads 14:33
• Trouble with other social media platforms 17:55
• Tips and tricks to building a community on a social media 20:20
• The power of social media platforms and engagement in established communities 22:30
• Fighting misinformation 25:13
• Platforms versus audience 27:15
• How would you like to see Threads change as a platform? 31:21
• What is the power of TikTok in terms of getting movement among communities? 33:31
• How do you create a profile on Threads? 40:30
• Level of engagement: Twitter vs. Threads 43:31
• The overwhelming number of platforms 52:29
• What is the best platform for physicians to use? 53:41
• Sharable content to post across other platforms 55:34
• Final thoughts 58:09
• Thanks for listening 1:02:13
Douglas H. Jones, MD, is the cofounder of Global Food Therapy, cofounder and president of Food Allergy Support Team and director of Rocky Mountain Allergy at Tanner Clinic. You can follow him on Threads @drdouglasjones.
Amy Comander, MD, DipABLM, is director of breast oncology and survivorship at the Massachusetts General Hospital Cancer Center in Waltham and at Newton-Wellesley, and medical director of the Massachusetts General Hospital Cancer Center in Waltham. She is director of the Lifestyle Medicine Program at the Massachusetts General Hospital Cancer Center. She is also an instructor in medicine at Harvard Medical School. You can follow her on Threads @dramycomander.
Shika Jain, MD, FACP, is an associate professor of medicine with tenure in the division of hematology, oncology and cell therapy at the University of Illinois Cancer Center in Chicago. She is the director of communication strategies in medicine and associate director of oncology communication and digital innovation. She also is consulting editor for Healio Women in Oncology, as well as host of Healio's Oncology Overdrive podcast. You can follow her on Threads @shikajainmd.
Dagny Zhu, MD, is a cornea, cataract, and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. You can follow her on Threads @dzeyemd.
Don S. Dizon, MD, FACP, FASCO, is head of community outreach and engagement at the Cancer Center at Brown University and head of the breast and pelvic malignancies program at Lifespan Cancer Institute. You can follow him on Twitter (X) and TikTok @drdonsdizon.
Mark A. Lewis, MD, is the director of gastrointestinal oncology at Intermountain Healthcare in Murray, Utah, and a medical oncologist specializing in cancers of the gastrointestinal tract and accessory organs. You can follow him on Twitter (X) @marklewismd.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD.
Disclosures: The moderators and panelists report no relevant financial disclosures. -
In this episode, host Shikha Jain, MD, speaks with the Patient Empowerment Network’s Tracy Rode about providing patients with tools for advocacy, developing accessible patient resources and more.
• Welcome to another exciting episode of Oncology Overdrive 1:11
• About Rode 1:23
• The interview 2:34
• Can you tell us about your journey and how you ended up in this space as such a strong voice for patient advocates? 2:52
• Tell me more about Patient Empowerment Network (PEN), what it does for patients and what it does for health care workers 9:06
• Jain and Rode on how health care workers can improve ways to communicate information to patients in ways they can absorb 14:03
• How do you suggest patients and physicians use the resources provided by organizations like PEN? What is the best way to incorporate education into a clinical visit? 19:06
• Rode and Jain on examples of how much easier it is today for patients to come across misinformation in media, and how organizations can help patients avoid this misinformation 21:50
• Jain and Rode on patient accessibility and benefits to understanding clinical trials 26:35
• Can you share how your cancer diagnosis impacted the way you transitioned into thinking about patient advocacy issues and your approach to them? 29:13
• If someone could only listen to the last two minutes of this episode, what would you want them to take away? 31:35
• How to contact Rode 34:13
• Thanks for listening 35:20
Tracy Rode is the executive director of the Patient Empowerment Network (PEN). Rode brings over two decades of non-profit leadership experience, including working with diverse patient populations to improve patient outcomes and increase access to care.We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Rode and the Patient Empowerment Network can be reached at powerfulpatients.org, or via LinkedIn, Facebook, and Twitter @power4patients.
Disclosures: Jain and Rode report no relevant financial disclosures. - Laat meer zien
